Sagent Pharmaceuticals Major Shareholder Unloads $2,609,929 in Stock (SGNT)
Sagent Pharmaceuticals (NASDAQ:SGNT) major shareholder Morgan Stanley Investment Mana sold 119,557 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $21.83, for a total transaction of $2,609,929.31. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
A number of analysts have recently weighed in on SGNT shares. Analysts at RBC Capital upgraded shares of Sagent Pharmaceuticals (NASDAQ:SGNT) from a “sector perform” rating to an “outperform” rating in a research note to investors on Wednesday, September 11th. They now have a $25.00 price target on the stock, up previously from $22.00. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of Sagent Pharmaceuticals (NASDAQ:SGNT) from $18.00 to $21.00 in a research note to investors on Wednesday, August 7th.
Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $22.96.
Sagent Pharmaceuticals (NASDAQ:SGNT) traded down 0.51% on Tuesday, hitting $21.33. 149,113 shares of the company’s stock traded hands. Sagent Pharmaceuticals has a one year low of $13.39 and a one year high of $24.27. The stock’s 50-day moving average is $22.71 and its 200-day moving average is $19.74. The company has a market cap of $601.5 million and a price-to-earnings ratio of 31.07.
Sagent Pharmaceuticals (NASDAQ:SGNT) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.46 EPS for the quarter. The company had revenue of $59.60 million for the quarter, compared to the consensus estimate of $59.27 million. On average, analysts predict that Sagent Pharmaceuticals will post $0.86 earnings per share for the current fiscal year.
Sagent Pharmaceuticals, Inc (NASDAQ:SGNT) is an injectable pharmaceutical company, which develops and sources products, which the Company sells in the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.